SUMOylation-Modified AAV2 Capsid for Gene Transfer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV vectors face limitations in transduction efficiency and immune response, which hinder their extensive use in gene therapy, particularly due to the inhibitory effects of SUMOylation and other post-translational modifications during the transduction process.
Innovation Solution
Modification of SUMOylation target sites on the AAV VP1 capsid protein by mutating lysine residues to glutamine, specifically at sites predicted by GPS-SUMO and SUMOplot, to reduce SUMOylation and enhance transduction efficiency, resulting in vectors like AAV2-K105Q that demonstrate improved gene expression and reduced immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If SUMOylation target sites are present on AAV VP1 capsid protein, then the vector can be produced using standard methods, but transduction efficiency is reduced due to inhibitory SUMOylation
Solution Approach 1:
The invention changes the amino acid sequence parameters of the VP1 capsid protein by mutating lysine residues (SUMOylation target sites) to arginine or glutamine residues. This parameter change prevents SUMOylation while maintaining capsid protein function, thereby resolving the contradiction between producibility and transduction efficiency.
Solution Approach 2:
The invention converts the harmful effect of SUMOylation inhibition into a benefit by strategically mutating specific lysine residues. The mutated residues maintain structural integrity while preventing the harmful SUMOylation modification, thus transforming a potential weakness into an improved transduction capability.
2Productivity
If lysine residues are mutated to prevent SUMOylation, then transduction efficiency increases, but capsid protein structure may be affected
Solution Approach 1:
The invention carefully selects which lysine residues to mutate based on their accessibility and importance for capsid structure. By changing parameters (amino acid sequence) at specific positions while maintaining overall composition, the invention achieves improved transduction without compromising structural stability.
Solution Approach 2:
The invention applies local quality changes by mutating only specific lysine residues that are accessible to SUMOylation enzymes, while leaving other lysine residues unchanged. This localized approach prevents SUMOylation at critical sites without affecting the overall capsid protein structure and function.
3Productivity
If multiple SUMOylation target sites are mutated, then transduction efficiency is significantly enhanced, but vector production complexity increases
Solution Approach 1:
The invention changes the amino acid sequence parameters at multiple specific positions in the VP1 capsid protein. By systematically mutating multiple SUMOylation target sites (e.g., K105Q, K105R, K620Q, K620R), the invention achieves synergistic enhancement of transduction efficiency while maintaining a relatively simple production process using standard molecular biology techniques.
Data Source
AI summary
The present invention provides for a process for producing a plurality of SUMOylation target-site modified AAV vectors, SUMOylation target-site modified AAV vectors, and application of the SUMOylation target-site modified AAV vectors in gene therapy. The present invention provides for manipulation of SUMOylation specific amino acids on AAV2 capsid protein, thereby regulating role of the same. Furthermore, the development of SUMOylation target modified AAV2 vectors presents an exciting opportunity for hepatic or ocular gene transfer with the safest AAV vector in human gene therapy applications. The plurality of SUMOylation target-site modified AAV vectors are not immunogenic in comparison to wildtype AAV2 vectors and possess significantly higher gene expression, with respect to wild type, thereby improving efficiency of hepatic and ocular gene transfer.